Morgan Stanley, Gilead

Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug developer shared initial mid-stage trial data for two antitumor agents developed using Sanofi’s (SNY) PRO-XTEN masking platform.
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture,
Gilead Sciences Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a five-day losing streak.
FierceBiotech3d
Galapagos splits in 2, laying off 40% of staff, shrinking pipeline and ending Gilead partnership
After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
This was the stock's fifth consecutive day of losses.
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
ENDPOINTS NEWS1d
Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
Morningstar1d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Armenian Reporter23h
ORG Partners LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...